Bridging Anticoagulation for NPO Patient with Prior DVT on Apixaban
Use therapeutic-dose low molecular weight heparin (LMWH), specifically enoxaparin 1 mg/kg subcutaneously twice daily or 1.5 mg/kg once daily, to bridge anticoagulation while the patient cannot take oral apixaban.
Rationale for LMWH Bridging
When apixaban must be held due to NPO status after a failed swallow screen, parenteral anticoagulation is necessary to maintain therapeutic anticoagulation for DVT treatment. The European Society of Cardiology guidelines explicitly recommend LMWH or fondaparinux over unfractionated heparin (UFH) when parenteral anticoagulation is initiated in patients without hemodynamic instability 1.
For patients with prior DVT requiring therapeutic anticoagulation:
- Enoxaparin 1 mg/kg subcutaneously twice daily is the standard therapeutic dose for VTE treatment 2
- Alternatively, enoxaparin 1.5 mg/kg once daily can be used 2
- This maintains therapeutic anticoagulation without the need for monitoring in most patients 1
Key Considerations for This Clinical Scenario
Timing of Apixaban Discontinuation
The patient's apixaban should be held while NPO, as the medication requires oral administration and cannot be given via nasogastric tube in this acute setting 3. Apixaban should be discontinued at least 24-48 hours before any planned procedure, but in the NPO setting due to failed swallow screen, it should be held immediately 4.
When Bridging IS Indicated
Bridging with therapeutic-dose LMWH is specifically recommended for patients at very high risk of recurrent VTE, which includes those within 3 months of an acute VTE event 2. The French perioperative guidelines note that bridging is NOT routinely needed except for very high thrombotic risk patients 4.
However, this patient's situation differs from elective surgery bridging:
- The patient is NPO due to medical necessity (failed swallow screen), not elective surgery
- There is no planned procedure with defined bleeding risk
- The patient requires ongoing therapeutic anticoagulation for DVT treatment
Specific LMWH Dosing
For therapeutic anticoagulation in DVT:
- Enoxaparin 1 mg/kg subcutaneously every 12 hours 2
- OR enoxaparin 1.5 mg/kg subcutaneously once daily 2
- Dalteparin 200 units/kg once daily (if cancer-associated) 5, 2
Monitoring Requirements
- No routine monitoring is needed for LMWH in patients with normal renal function 4
- In patients with severe renal impairment (CrCl <30 mL/min), consider UFH instead of LMWH due to renal elimination concerns 5, 1
- Monitor renal function if the patient's medical condition could affect kidney function 4
Resuming Apixaban
Once the patient passes the swallow screen and can safely take oral medications:
Resume apixaban at the appropriate dose based on treatment phase 3:
- If within first 7 days of DVT treatment: 10 mg twice daily
- If beyond 7 days: 5 mg twice daily
- If beyond 6 months and considering extended therapy: 2.5 mg twice daily may be considered 2
Timing of transition from LMWH to apixaban:
Important Caveats
Contraindications to LMWH
- Severe renal impairment (CrCl <30 mL/min): Use UFH with aPTT monitoring instead 5, 1
- Active major bleeding: Hold all anticoagulation until bleeding controlled
- Heparin-induced thrombocytopenia (HIT): Use fondaparinux instead 5
Special Populations
- Cancer patients: LMWH remains an acceptable option, though DOACs are now preferred when oral intake is possible 5, 6, 7
- Pregnancy: LMWH is the anticoagulant of choice; DOACs are contraindicated 1
Duration Considerations
The patient should remain on therapeutic anticoagulation (whether LMWH or apixaban) for at least 3 months total from the DVT diagnosis 1, 8, 1, 6. Extended therapy beyond 3-6 months depends on whether the DVT was provoked or unprovoked 1, 6.